ThermoGenesis Holdings, Inc. Overview
Pro stress-test →ThermoGenesis Holdings develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. The company markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market.
Strategic Profile
Pro stress-test →ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. ThermoGenesis is transitioning to a CDMO model, launching 12 ReadyStart cGMP Suites projected to generate $10-$16 million annually. The company operates as a micro-cap public entity facing significant market capitalization challenges as of mid-2026.
Competitive Landscape
Pro stress-test →ThermoGenesis competes with larger cell-therapy infrastructure providers and emerging CDMO platforms in the cell and gene therapy manufacturing space. The fragmented competitive landscape includes specialized biotech service providers and established contract manufacturers. The company's small scale and challenged financial position limit competitive reach relative to larger established players in cell processing automation.
Industry Context
ThermoGenesis Holdings, Inc. operates in Cell and gene therapy manufacturing automation.
Key facts
Headquarters: Rancho Cordova, US · Revenue: $9.6M · Market cap: $1.75M